Recalls of generic Zantac believed to be contaminated by a carcinogen continue to flood in. Two other firms have declared recalls of ranitidine heartburn meds in 150 mg and 300 mg doses. The news arrived even as the degree of the drug returns increased with Mylan’s impromptu recall of three lots of nizatidine capsules last week because the API in them also held dangerous levels of NDMA.
Shortly after the Federal officials announced the voluntary recalls of some pharmacies over NDMA, a drug filled with a potential human carcinogen, many other pharmacies have recalled the common variety of heartburn drug Zantac, called ranitidine, from shelves.
Additional generic editions of Zantac are being taken down from pharmacy shelves after officials detected low levels of a possible carcinogens in the heartburn medication.
The Stryker Tritanium Acetabular Shell, which restores the human hip socket, is built from a titanium alloy covered with a unique kind of porous foam. The foam enables bone cells to bind with it and grow, thereby increasing joint stability. However, a 2018 report in the journal Arthroplasty Today by doctors at NYU Langone Orthopedic Hospitals described five hip implant failures related to Stryker’s Tritanium cups between 2011 and 2016.
The Financial Industry Regulatory Authority (FINRA) published its 2019 Report on Examination Findings and Observations on October 16, 2019. This marks the third published annual report of FINRA finding which in an unprecedented departure from the prior reports, distinguishes “findings” (determinations that a firm or registered person has violated SEC, FINRA or other relevant rules) from “observations” (suggestions as to how a firm might improve control of its environment).
FINRA is far from a shadowy regulatory agency. They do their best to find themselves in the public eye, if only to keep investors informed on current regulations and scams. They also keep an exhaustive database of the professional records of all registered broker-dealers and financial advisors; the database is online and searchable. FINRA’s BrokerCheck is a mighty tool for investors seeking to learn more about their advisors; it’s one of many tools and rules that investors can use to protect themselves against fraud and malfeasance.
The last few months have been a difficult time for many investors. The stock market has taken a major dive, closing out 2018 with the worst performing December since The Great Depression. With so much volatility, it’s crucial that investors have a carefully planned portfolio with an adequate amount of diversification. Above all, that portfolio should match the individual investors risk tolerance and investment objectives. That match must be valid from the day it was made until today. A portfolio that worked for an individual investor in a bull market may be a terrible match for that same person in a bear market.
Thanks to a recent decision by the Fifth Circuit, it appears that brokers will, once again, get off the hook when it comes putting their clients' interests in front of their own. Into the breach has stepped an idea that has been kicking around for a years now, but which may be the best of several uninspiring options to compel brokers to act more responsibly toward investors: The Oath.
The Chairman of the Council of Economic Advisors has ruffled some serious Wall Street feathers with the release of a recent report suggesting that Americans with 401(k) retirement accounts could be losing $8 billion to $17 billion per year due to opportunistic trading by the brokers managing their accounts.
By introducing an inappropriate amount of risk into your investment portfolio through oil and gas MLP stocks (or any other publicly or privately-traded security or product, for that matter), you may be able to pursue your losses due to bad advice through the FINRA (Financial Industry Regulatory Authority, the securities industry’s self-regulating body) arbitration process.
2332 South Broad Street
Philadelphia PA 19145
p: 215 462 3330 / f: 215-567-1941
